ARTICLE | Emerging Company Profile
Pellino play
How Bridge's first program attacks inflammatory disease on multiple fronts
October 10, 2016 7:00 AM UTC
Bridge Biotherapeutics Inc. has licensed the first of what it hopes will be many assets it can use its translational expertise to bring through Phase II proof of concept. The South Korean company is seeking first-in-class small molecules from academics, biotechs or pharmas in Asia.
Its first program, BBT-401, is an N-terminal lipidated 4aa peptide targeting pellino E3 ubiquitin protein ligase 1 (PELI1; pellino-1)...